Irbesartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 0093-8232

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 0093-8232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

A line graph showing the percentage of subjects with systolic blood pressure below 140 mmHg versus baseline systolic blood pressure measurements ranging from 140 to 220 mmHg. The graph compares results from different studies of Irbesartan and Hydrochlorothiazide, Irbesartan alone, and Hydrochlorothiazide alone, as indicated by distinct lines and a legend within the figure.*

FDA Label Image

Irbesartan And Hydrochlorothiazide Tablets Usp 300 mg/12.5 mg 30s Label (Image 10)

Packaging label for Irbesartan and Hydrochlorothiazide Tablets USP, 300 mg/12.5 mg strength. The label indicates a count of 30 tablets and is labeled by Teva Pharmaceuticals USA Inc. It includes dosage information, storage instructions to keep at 20° to 25°C (68° to 77°F), and warnings to keep out of reach of children.*

FDA Label Image

Image 2

A line graph depicting the percentage of patients with systolic blood pressure (SBP) under 130 mmHg relative to baseline SBP (mmHg). It compares results from studies involving Irbesartan alone, Hydrochlorothiazide (HCTZ) alone, and their combination across two different studies labeled Study V and Study VI.*

FDA Label Image

Image 3

A line graph showing the percentage of baseline diastolic blood pressure (DBP) versus baseline DBP in mmHg. The graph compares different study results labeled as Irbesartan and HCTZ Study V, Irbesartan Study V, HCTZ Study V, Irbesartan and HCTZ Study VI, and Irbesartan Study VI, using distinct line styles and colors for each.*

FDA Label Image

Image 4

A line graph depicting the percentage of subjects with baseline diastolic blood pressure (DBP) below 80 mmHg against baseline DBP values ranging from 90 to 130 mmHg. The graph compares four studies involving Irbesartan and Hydrochlorothiazide (HCTZ), with distinct lines representing Irbesartan and HCTZ Study V, Irbesartan Study V, HCTZ Study V, Irbesartan and HCTZ Study VI, and Irbesartan Study VI.*

FDA Label Image

Image 5

Chemical structure diagram of the active ingredient, Irbesartan. The diagram shows the molecular arrangement including rings and functional groups characteristic of Irbesartan's chemical composition.*

FDA Label Image

Image 6

Chemical structure diagram depicting Irbesartan, the active ingredient in the combination product Irbesartan and Hydrochlorothiazide by Teva Pharmaceuticals USA Inc.*

FDA Label Image

Image 7

A scatter plot graph displaying the relationship between Irbesartan dose (mg/day) on the x-axis and the effect in mmHg on the y-axis. The data points show an initial steep increase that plateaus as the dose reaches higher levels, indicating a dose-response curve for Irbesartan.*

FDA Label Image

Image 8

A scatter plot with a fitted curve showing the relationship between Irbesartan dose (mg/day) on the x-axis and a variable measured in mmHg on the y-axis. Data points are spread with a curve indicating an increasing response that plateaus at higher doses.*

FDA Label Image

Image 9

Label for Irbesartan and Hydrochlorothiazide Tablets USP 150 mg/12.5 mg by Teva Pharmaceuticals USA Inc. The label includes NDC 0093-8238-56, indicates a bottle with 30 tablets, and storage instructions to keep at 20° to 25°C (68° to 77°F). Prescriptions only. Lot and expiration date fields are empty.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.